Skip to main content

Topic

Biosimilars

856 published works

  1. Big Molecule Watch

    Amgen, Hikma, and Gedeon Settle Denosumab BPCIA Case

    By Timothy Beavers

    On November 24, 2025, the U.S. District Court for the District of New Jersey entered a Consent Judgment and Injunction resolving the denosumab BPCIA litigation between Amgen, Inc. and Amgen…

  2. Big Molecule Watch

    Register Today: Webinar Series: An Overview of the Biosimilars Market in China, and Comparison with the US Market

    By Sabrina Tredwell

    Join Kevin DeJong, Huiya Wu, and David Chen in our next webinar, “An Overview of the Biosimilars Market in China, and Comparison with the US Market” on December 17th at…

  3. Big Molecule Watch

    European Commission Approves Alvotech’s and Teva’s Denosumab Biosimilars

    By Sarah Adam

    On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and XGEVA® (denosumab) in the European Economic Area. AVT03 is…

  4. Big Molecule Watch

    Formycon Announces New Dupilumab Biosimilar Candidate

    By Sam Herron

    On November 17, 2025 Formycon AG (“Formycon”) announced development of a dupilumab biosimilar, FYB208, referencing Regeneron and Sanofi’s DUPIXENT.  Dupilumab is a monoclonal antibody therapy designed to treat immunological disease…

  5. Big Molecule Watch

    Sandoz Launches Natalizumab Biosimilar

    By Christopher Cassella

    On November 17, 2025, Sandoz announced the launch of TYRUKO® (natalizumab-sztn) in the United States as the first and only biosimilar for the treatment of relapsing forms of multiple sclerosis.  TYRUKO® was approved…

  6. Big Molecule Watch

    Sandoz and EirGenix Enter Licensing Agreement to Commercialize Proposed Pertuzumab Biosimilar

    By Riley Wyberg

    On November 12, 2025, Sandoz announced a licensing agreement with EirGenix to commercialize EG1206A (pertuzumab), a proposed biosimilar of Genentech’s PERJETA® (pertuzumab). Under the terms of the agreement, Sandoz has…

  7. Big Molecule Watch

    Amgen Files BPCIA Complaint Against Alkem Related to Denosumab Biosimilar

    By Natasha Daughtrey

    On November 14, 2025, Amgen, Inc. (“Amgen”) launched another BPCIA denosumab litigation when it filed a complaint in the U.S. District Court for the District of New Jersey against Alkem…

  8. Big Molecule Watch

    FDA Approves Accord BioPharma’s Denosumab Biosimilars

    By Christopher Cassella

    On November 20, 2025, the FDA approved Accord BioPharma’s denosumab biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu), which reference Amgen’s PROLIA® and XGEVA®, respectively.  This marks the eighth set of denosumab biosimilars…

  9. Big Molecule Watch

    Regeneron Moves to Strike and Dismiss Amgen’s Counterclaims in Aflibercept Litigation

    By Allegra Padula|Kevin DeJong

    On November 12, 2025, Regeneron filed a Motion to Strike Certain Affirmative Defenses and Dismiss Certain Counterclaims against Amgen in the aflibercept patent litigation in the U.S. District Court for…

  10. Big Molecule Watch

    FDA Approves Shanghai Henlius’s Interchangeable Pertuzumab Biosimilar

    By Riley Wyberg

    On November 13, 2025, the FDA approved Shanghai Henlius Biologics Co. Ltd.’s POHERDY (pertuzumab-dpzb) as an interchangeable biosimilar to Genentech’s PERJETA (pertuzumab).  This is the first pertuzumab biosimilar to receive…